Loading
TC
Trulieve Cannabis Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by May Richard S., was filed 13 Aug 2025.
Trulieve Cannabis Corp.: what insiders have been doing
Trulieve Cannabis Corp., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 19 insiders have disclosed 33 filings since 18 October 2025.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
No insider has bought Trulieve Cannabis Corp. shares on the open market in the past twelve months. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
With 33 filings in twelve months, the company is more active than the median of 19 filings across the 5,812 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 26 purchases and 1 sale. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 1.18 bn USD and net income of -122.2 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
149
Thresholds
n/a
Buy Volume
€958,306
26 ops. · all time
Sell Volume
€12,585
1 ops. · all time
Who traded when
BuySaleRichard S. May2 buys
Collins Gina1 buy
Eric Powers1 buy
Getman Wes1 buy
Kyle Landrum1 buy
Morreau Jane C1 buy
+7 other insiders
Since the insiders bought
- +0.0%Entry US$0.00 · Close at T+365 US$0.00
- -90.0%Entry US$0.00 · Close at T+365 US$0.00
- -90.0%Entry US$0.00 · Close at T+365 US$0.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$1B
Gross profitUS$612.3M60% margin
EBITDA-US$4.3M-0% margin
Net income-US$217.6M0.0% margin
Valuation
Beta-488.23
Profitability & ownership
ROA-1628.4%
Last declaration on 26 June 2026
Declarations149 total
136,811 shares@ €5.40868.2% of flowSubordinate Voting SharesTSXSEDI:4740996
300,000 shares@ €5.119518.4% of flowSubordinate Voting SharesTSXSEDI:4740562
400,000 shares@ €5.052529.7% of flowSubordinate Voting SharesTSXSEDI:4739687
380,000 shares@ €5.238129.3% of flowSubordinate Voting SharesTSXSEDI:4739684
204,815 shares@ €5.752742.3% of flowSubordinate Voting SharesTSXSEDI:4739076
139,846 shares@ €5.83429.3% of flowSubordinate Voting SharesTSXSEDI:4739073
137,535 shares@ €5.753928.4% of flowSubordinate Voting SharesTSXSEDI:4739071
2,500,000 sharesSubordinate Voting SharesTSXSEDI:4739065
1,699,007 shares@ €9.1246COMMONSEC144:0000107476-26-000009
2,500,000 sharesSubordinate Voting SharesTSXSEDI:4683401
28,711 shares0Subordinate Voting SharesSEC:0002118068-26-000002:0
58,594 shares0Subordinate Voting SharesSEC:0002044797-26-000002:0
23,438 shares0Subordinate Voting SharesSEC:0001841329-26-000002:0
820,000 shares0Subordinate Voting SharesSEC:0001841319-26-000002:0
23,438 shares0Subordinate Voting SharesSEC:0001840008-26-000002:0
23,438 shares0Subordinate Voting SharesSEC:0001835221-26-000002:0
58,594 shares0Subordinate Voting SharesSEC:0001835213-26-000002:0
58,594 shares0Subordinate Voting SharesSEC:0001835207-26-000002:0
23,438 shares0Subordinate Voting SharesSEC:0001626839-26-000002:0
23,438 shares0Subordinate Voting SharesSEC:0001259381-26-000002:0
58,594 shares0Subordinate Voting SharesSEC:0002107378-26-000003:0
58,594 shares0Subordinate Voting SharesSEC:0001835197-26-000002:0
23,438 shares0Subordinate Voting SharesSEC:0001561397-26-000002:0
23,438 shares0Subordinate Voting SharesSEC:0001229121-26-000002:0
25 of 149 declarations
About Trulieve Cannabis Corp.
Trulieve Cannabis Corp. is a United States cannabis company focused on medical cannabis and, in certain jurisdictions, adult-use cannabis. For investors, the important market context is that the company is tied to the U.S. public-markets ecosystem and SEC reporting, while its securities are primarily associated with North American trading venues rather than a mainstream U.S. national exchange listing. Trulieve’s corporate headquarters is in Quincy, Florida, and the company operates as a vertically integrated multi-state operator, meaning it controls cultivation, processing, distribution, and retail in its licensed markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1754195/000162828025008421/tcnnf-20241231.htm?utm_source=openai))
Trulieve’s origins are in Florida, where it says it won the state’s first medical marijuana license in 2015 and completed its first sale in 2016. That early foothold gave the company a launch pad in one of the most important state-level cannabis markets in the United States. Over time, Trulieve expanded from a Florida-centric operator into a broader multi-state platform, still with Florida as a core profit pool. The company’s model is notable for its vertical integration, which is strategically valuable in cannabis because regulatory complexity, cultivation efficiency, and retail execution all influence margins and cash generation. ([investors.trulieve.com](https://investors.trulieve.com/faqs?utm_source=openai))
Read moreShow less
Its main business lines include retail dispensary sales and wholesale distribution of branded cannabis products, supported by internal cultivation and manufacturing capabilities. Product categories typically include flower, oils, concentrates, edibles, and wellness-oriented cannabis products. Trulieve positions its products around quality, compliance, and customer trust, emphasizing state-approved, climate-controlled cultivation environments. Competitively, the company benefits from brand recognition, a large Florida footprint, and operational scale in a fragmented industry where many competitors remain single-state or regional players. That scale can support pricing discipline and better cost absorption, although cannabis remains a highly regulated and volatile category. ([trulieve.com](https://www.trulieve.com/about/?utm_source=openai))
Geographically, Trulieve remains heavily U.S.-focused, with operations in multiple states and an especially deep presence in Florida. This domestic concentration simplifies the operating model relative to more global consumer-health names, but it also keeps the investment case closely tied to U.S. state and federal policy. Recent company updates have been constructive: Trulieve reported full-year 2025 results in February 2026 and highlighted approximately 60% gross margin and record cash flow generation, while also continuing financial optimization and retail expansion. At the sector level, the federal reclassification debate around cannabis in the United States has remained an important catalyst, potentially improving tax treatment, research access, and banking access if regulatory momentum continues. ([prnewswire.com](https://www.prnewswire.com/news-releases/trulieve-reports-fourth-quarter-and-full-year-2025-results-with-60-gross-margin-and-record-cash-flow-generation-302697731.html?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
